Navigation Links
Shire plc: First Quarter 2009 Results Date Notification - April 30, 2009
Date:4/20/2009

DUBLIN, Ireland, April 20 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, will announce first quarter 2009 earnings on Thursday April 30, 2009.

    Results press release will be issued at:        12:00 BST / 07:00 EDT

    Investor conference call time:                  14:30 BST / 09:30 EDT

Live conference call for investors:

Angus Russell, Chief Executive Officer and Graham Hetherington, Chief Financial Officer will host the investor and analyst conference call at 14:30 BST/9:30 EDT.

    The details of the conference call are as follows:

    UK dial in:              0808-100-5150
    US dial in:              1-866-804-8688 or 1-718-354-1175
    International dial in:   +44(0)1296-480-100
    Password/Conf ID:        228 831

    Live Webcast:http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2

Replay:

A replay of the presentation will be available for two weeks by phone and by webcast for one year. Details can be found on our Investor Relations website http://www.shire.com/shire/InvestorRelations/index.jsp?tn=2 .

Notes to editors

Shire PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.


'/>"/>
SOURCE Shire Plc
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Shire Files Lawsuit Against Natco Pharma for Infringement of FOSRENOL(R) (lanthanum carbonate) Patents
2. Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD
3. Publication of Shire plcs Annual Report 2008
4. Shires Project Playground Gives Boost to Philadelphia
5. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
6. Shire Files Lawsuit Against Barr Laboratories for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patents
7. Shire Announces Opening of Office in Japan
8. Shire to Enter European ADHD Market With the Acquisition of EQUASYM(R) IR and XL
9. Shire Delivers Excellent Growth for the Year, With the new Product Portfolio Achieving Sales of $1 Billion
10. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
11. Shire plc: Change to Directors Details
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... ... 2017 , ... We are proud to announce the successful ... Dilworth, MN site. The inspection took place Monday, July 31st through Friday, August ... a routine Bioresearch Monitoring Program (BIMO) with the USFDA wherein multiple Dermatology Vasoconstriction ...
(Date:8/15/2017)... After spending the past two years building a state-of-the-art ... GeneFo now offers this platform to healthcare stakeholders (hospitals, foundations, biopharma ... and data collection vis a vis their members, under their own ... of this offer. ... ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of the largest Asian exhibitions for analytical and scientific instruments. This year’s symposium, ... be “New Approaches in Mass Spectrometry for Bioanalytical Applications.” This dynamic presentation will ...
(Date:8/15/2017)... , ... August 15, 2017 , ... The Conference ... on Immuno-Oncology 360° (IO360°) programming through a series of upcoming panels and events. The ... 7-9, 2018, at The Roosevelt Hotel in New York City. , “With our experience ...
Breaking Biology Technology:
(Date:4/3/2017)... 3, 2017  Data captured by IsoCode, ... detected a statistically significant association between the ... treatment and objective response of cancer patients ... predict whether cancer patients will respond to ... well as to improve both pre-infusion potency testing ...
(Date:3/30/2017)... YORK , March 30, 2017 Trends, ... type (physiological and behavioral), by technology (fingerprint, AFIS, iris ... voice recognition, and others), by end use industry (government ... and immigration, financial and banking, and others), and by ... Europe , Asia Pacific , ...
(Date:3/27/2017)... CENTRE, N.Y. , March 27, 2017 /PRNewswire-USNewswire/ ... Healthcare Information and Management Systems Society (HIMSS) Analytics ... Outpatient EMR Adoption Model sm . In addition, ... 12% of U.S. hospitals using an electronic medical ... CHS for its high level of EMR usage ...
Breaking Biology News(10 mins):